Amylin Pharmaceuticals to Webcast Update on SYMLIN(R) Regulatory Status
September 17 2004 - 5:20PM
PR Newswire (US)
Amylin Pharmaceuticals to Webcast Update on SYMLIN(R) Regulatory
Status SAN DIEGO, Sept. 17 /PRNewswire-FirstCall/ -- Amylin
Pharmaceuticals, Inc. (NASDAQ:AMLN) will webcast an update on the
regulatory status of SYMLIN(R) (pramlintide acetate) on Monday,
September 20, 2004 at 12:00 p.m. ET (9:00 a.m. PT). SYMLIN(R) is
currently under review with the FDA for the treatment of people
with type 1 and insulin-using type 2 diabetes. Ginger L. Graham,
President and Chief Executive Officer of Amylin Pharmaceuticals,
will lead the call. The call will be webcast live through Amylin's
corporate website, and a recording will be made available following
the close of the call. To access the webcast, please log on to
http://www.amylin.com/ approximately fifteen minutes prior to the
call to register, download and install any necessary audio
software. A recording will be available by phone for 24 hours
beginning approximately one hour after the close of the call and
can be accessed at (888) 286-8010 (domestic) or (617) 801-6888
(international), passcode 61201960. Amylin Pharmaceuticals is
committed to improving the lives of people with diabetes and other
metabolic diseases through the discovery, development and
commercialization of innovative, cost-effective medicines.
DATASOURCE: Amylin Pharmaceuticals, Inc. CONTACT: Mark G. Foletta,
Vice President of Finance and Chief Financial Officer of Amylin
Pharmaceuticals, Inc., +1-858-552-2200 Web site:
http://www.amylin.com/
Copyright
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jul 2023 to Jul 2024